Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 34CNS 4Lymphoid 3Gynecologic 3Dermatologic 3Tumor-Agnostic 2Thoracic 2Sarcoma 2Other solid neoplasm 2Endocrine 2Other hematologic neoplasm 1NET 1Genitourinary 1Gastrointestinal 1

Conditions

Neuroendocrine Tumors 1Neoplasms by Site 1Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Breast Neoplasms 1Breast Diseases 1

Interventions

Everolimus 32Octreotide 15Cisplatin 14pasireotide 13Sunitinib 13Temozolomide 11pembrolizumab 10Etoposide 10Doxorubicin 10lanreotide 9Magnetic Resonance Spectroscopy 9Bevacizumab 9lutetium Lu 177 dotatate 8gallium Ga 68 dotatate 8Sorafenib 8Paclitaxel 83-Iodobenzylguanidine 8lenvatinib 7pazopanib 6Radiotherapy 6Positron Emission Tomography Computed Tomography 6Nivolumab 6surufatinib 5cabozantinib 5avelumab 5Thyrotropin Alfa 5Surgical Procedures, Operative 5Radiosurgery 5Mitotane 5Irinotecan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × ribociclib × Endocrine × Clear all
NCT03070301 2024-10-10

A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
21 enrolled 8 charts
EndocrineNET

Neuroendocrine Tumors

NCT02422615 2023-11-30

MONALEESA-3

Novartis

Phase 3 Completed
726 enrolled 17 charts 1 FDA
BreastEndocrine

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡